Ignite Creation Date:
2024-10-26 @ 3:39 PM
Last Modification Date:
2024-10-26 @ 3:39 PM
Study NCT ID:
NCT06581042
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-08-29
Brief Title:
Study to Assess Treatment Patterns and Outcomes With Upadcitinib in Adult Participants With Inflammatory Bowel Disease in Belgium
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Understanding Local TReatment Patterns and Outcomes With upAdacitinib in IBD Patients in Belgium
Status:
RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Crohns disease CD is an incurable chronic inflammatory disorder of the gastrointestinal tract Ulcerative colitis UC is an idiopathic chronic inflammatory disease affecting the colon This study will assess the long-term effectiveness and safety of upadacitinib in real-world clinical practice in adult participants with moderate to severe ulcerative colitis UC and crohns disease CD
Upadacitinib is an approved drug for treating ulcerative colitis UC and Crohns disease CD Approximately 280 participants who are prescribed Upadacitinib by their physician in accordance with local label will be enrolled in 8 sites across Belgium
Participants will receive upadacitinib as prescribed by their physician according to their routine clinical practice and local label Participants will be followed for up to 3 years
There is expected to be no additional burden for participants in this trial Participants will attend regular visits during the study at a hospital or clinic according to their routine clinical practice
Upadacitinib is an approved drug for treating ulcerative colitis UC and Crohns disease CD Approximately 280 participants who are prescribed Upadacitinib by their physician in accordance with local label will be enrolled in 8 sites across Belgium
Participants will receive upadacitinib as prescribed by their physician according to their routine clinical practice and local label Participants will be followed for up to 3 years
There is expected to be no additional burden for participants in this trial Participants will attend regular visits during the study at a hospital or clinic according to their routine clinical practice
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None